Novel inhibitors against COVID-19 main protease suppressed viral infection

Abstract excerpt

<h4>Summary</h4> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can cause severe disease with high mortality rates, especially among older and vulnerable populations. Despite the recent success of vaccines and approval of first-generation anti-viral inhibitor against SARS-CoV-2, an expanded arsenal of anti-viral compounds that limit viral replication and ameliorate...

Topics

Open a Topic to create a Post that cites this publication.

• Computational Drug Discovery Methods
• COVID-19 Clinical Research Studies
• Influenza Virus Research Studies
• interferon and immune responses
• Pharmacological Receptor Mechanisms and Effects
• RNA and protein synthesis mechanisms
• SARS-CoV-2 and COVID-19 Research
• Viral gastroenteritis research and epidemiology

Identifiers and source

Literature Corpus work

b4843b71-de00-5e2b-901e-1dcbeab03999

DOI

10.1101/2022.11.05.515305